Icon plc Aktie
263,10 €
Deine Einschätzung
Icon plc Aktie
Was spricht für und gegen Icon plc in den nächsten Jahren?
Pro
Kontra
Rendite von Icon plc im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Icon plc | 0,38 % | 0,00 % | -10,20 % | 6,91 % | 1,78 % | - | - |
Alkermes plc | 0,81 % | 3,33 % | 1,64 % | -10,79 % | -0,80 % | -1,59 % | 28,50 % |
Ironwood Pharmaceuticals | 1,51 % | 6,32 % | 3,06 % | -51,03 % | -60,39 % | -60,39 % | -54,18 % |
Arrowhead Pharmaceuticals Inc. | 3,93 % | -1,60 % | -9,20 % | -28,99 % | -33,58 % | -66,10 % | -29,55 % |
Kommentare
News
ICON Survey Highlights Scale of Focus on Precision Therapies in Increasingly Complex Oncology Landscape
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent survey of over 100 professionals engaged in
ICON plc to Present at the Baird 2024 Global Healthcare Conference
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Baird 2024 Global
ICON Announces Appointment of New Chief Financial Officer
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO).